Ocugen Patient Engagement (@ocugenpe) 's Twitter Profile
Ocugen Patient Engagement

@ocugenpe

ID: 1645796765357182982

calendar_today11-04-2023 14:31:48

104 Tweet

510 Followers

3 Following

Ocugen Patient Engagement (@ocugenpe) 's Twitter Profile Photo
Ocugen Patient Engagement
@ocugenpe

2 months ago

Today, Dr. Benjamin Bakall, MD, PhD presented a late breaking abstract titled, “One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa” during the ASRS Annual meeting in Stockholm, Sweden.

Today, Dr. Benjamin Bakall, MD, PhD presented a late breaking abstract titled, “One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa” during the ASRS Annual meeting in Stockholm, Sweden.